Wynne R D, Crampton E L, Hind I D
Eur J Clin Pharmacol. 1985;28(6):659-64. doi: 10.1007/BF00607911.
The pharmacokinetic and haemodynamic effects of a 200 mg oral dose of BTS 49 465 (7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone) were investigated in a double-blind placebo controlled study. BTS 49 465 was rapidly absorbed and cleared from the systemic circulation with a half-life of 1.6 h by oxidation to the sulphone metabolite. The metabolite was cleared with a half-life of 37.6 h. Saliva concentrations of both BTS 49 465 and its metabolite correlated well with the plasma concentrations. Compared to placebo, BTS 49 465 produced statistically significant reductions in blood pressure and increases in heart rate both supine and after a 60 degrees head up tilt. The time course of the haemodynamic changes suggested that the sulphone metabolite contributed to the overall hypotensive response. Plasma Renin Activity was only marginally elevated and there was no evidence of acute fluid retention. BTS 49 465 was well tolerated in terms of haematological and biochemical parameters and subjective side-effects.
在一项双盲安慰剂对照研究中,对口服200毫克BTS 49 465(7-氟-1-甲基-3-甲基亚磺酰基-4-喹诺酮)的药代动力学和血流动力学效应进行了研究。BTS 49 465经氧化生成砜代谢物后,迅速从体循环中吸收并清除,半衰期为1.6小时。该代谢物的半衰期为37.6小时。BTS 49 465及其代谢物的唾液浓度与血浆浓度相关性良好。与安慰剂相比,BTS 49 465在仰卧位和60度头高位倾斜后,血压均有统计学意义的显著降低,心率增加。血流动力学变化的时间过程表明,砜代谢物促成了总体降压反应。血浆肾素活性仅略有升高,且无急性体液潴留的证据。就血液学和生化参数以及主观副作用而言,BTS 49 465耐受性良好。